Combined Screening + PLGF with NIPT (Delfia)

Combined Screening + PLGF with NIPT (Delfia)

Overview

Combined Screening + PLGF with NIPT (Delfia) is an advanced prenatal screening package that combines first-trimester maternal serum markers, Placental Growth Factor (PLGF), and Non-Invasive Prenatal Testing (NIPT) to provide a comprehensive assessment of fetal chromosomal abnormalities and pregnancy-related complications.

Why is this test done?

• Screens for common chromosomal conditions such as:
  • Trisomy 21 (Down Syndrome)
  • Trisomy 18 (Edwards Syndrome)
  • Trisomy 13 (Patau Syndrome)
• Assesses the risk of pre-eclampsia using PLGF.
• Provides highly accurate prenatal genetic screening without risk to the fetus.
• Supports informed clinical decision-making during pregnancy.

What does the package include?

• First Trimester Combined Screening (Delfia)
• PLGF (Placental Growth Factor)
• NIPT (Non-Invasive Prenatal Testing)
• Maternal serum biochemical markers
• Risk assessment report integrated with maternal age and clinical information

Who should consider this test?

• Pregnant women between 10 and 13 weeks + 6 days of gestation.
• Women aged 35 years or older.
• Those with a family history of genetic disorders.
• Pregnancies with abnormal ultrasound findings.
• Women seeking a highly accurate prenatal screening option.

Sample Required

• Maternal Blood (Serum/EDTA Blood)

Preparation

• No fasting is required.
• Carry pregnancy dating scan/ultrasound details and relevant clinical information if available.

Benefits

• High detection rate for major chromosomal abnormalities.
• Early identification of pregnancies at increased risk.
• Non-invasive and safe for both mother and baby.
• Improved assessment of pre-eclampsia risk with PLGF.
• Helps guide appropriate follow-up testing and pregnancy management.

When is the ideal time for testing?

The test is generally recommended between 10 and 13 weeks + 6 days of pregnancy for optimal screening performance.

Note: This is a screening test, not a diagnostic test. A high-risk result may require confirmation through diagnostic procedures such as chorionic villus sampling (CVS) or amniocentesis, as advised by an obstetrician or fetal medicine specialist.